Since its founding in 2015 by a leading team of viral research scientists in Germany, Atriva has progressed immensely with the development of a small molecule viral replication inhibitor. We announced our participation in its seed round of financing back in July 2017, and the participation of the co-lead investor High-Tech Gründerfonds in September of the same year.
Since then, their lead product ATR-002, a first-in-class inhibitor targeting host cell MEK, has completed preclinical development and a request for scientific advice has recently been filed at a European regulatory agency. Atriva plans to start its Phase 1 study in healthy volunteers in 2019. Atriva has just announced the first closing of its series A financing round, which provides them with capital to enter first-in-humans clinical testing.
InSynchrony Ventures is delighted to continue supporting the development of this novel and potentially broadly active therapy.
Copyright © 2019 InSynchrony Ventures. All rights reserved. Creation by Netfolie.com